Clinical Trials Directory

Trials / Terminated

TerminatedNCT04852822

Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Multicenter Evaluation of SARS-CoV-2 Vaccines in Patients With CLL/SLL

Status
Terminated
Phase
Study type
Observational
Enrollment
350 (actual)
Sponsor
University of Washington · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study evaluates the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are types of blood cancer that begin in cells of the immune system. CLL/SLL and the medications used to treat these conditions may change the way vaccines work in a patient's body. The purpose of this study is to find out if patients with CLL/SLL make antibodies, or have an immune response, to the SARS-CoV-2 vaccines. Information gained from this study may help researchers better understand how effective the vaccines work in preventing COVID-19 (coronavirus disease 2019) in patients with CLL and SLL.

Detailed description

OUTLINE: For patients who have not been vaccinated at the time of enrollment, they will undergo collection of blood samples prior to the first vaccine dose, just before the second vaccine dose, and then at 1, 6, and 12 months after the second vaccine dose. Patients' medical records are also reviewed. For patients enrolled after vaccination, they will undergo collection of blood samples at 1-4, 6, and 12 months after completing the vaccination series. Patients who receive booster dose also undergo collection of blood samples at 1, 6, and 12 months post final booster dose. After completion of study, patients are followed up every 6 months for 2 years.

Conditions

Interventions

TypeNameDescription
PROCEDUREBiospecimen CollectionUndergo collection of blood samples
OTHERElectronic Health Record ReviewMedical records are reviewed

Timeline

Start date
2021-03-18
Primary completion
2023-01-01
Completion
2024-07-01
First posted
2021-04-21
Last updated
2024-08-02

Locations

11 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT04852822. Inclusion in this directory is not an endorsement.